Esophageal cancer
Conditions
Interventions
Neoadjuvant Therapy Group for Esophageal Cancer:Toripalimab 240 mg administered via intravenous infusion every three weeks. Albumin-bound paclitaxel 260 mg/m2 administered via intravenous infusion onc
Sponsors
Gansu Provincial Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: - Age between 18 and 75 years, regardless of gender. - Histologically confirmed locally advanced esophageal squamous cell carcinoma (Stage II–III). - ECOG performance status score of 0 or 1. - Planned surgical intervention following neoadjuvant therapy. - The baseline and post-treatment CT image data were of sufficient quality for evaluation.
Exclusion criteria
Exclusion criteria: - Presence of concomitant malignant tumors or severe comorbidities. - Prior receipt of immunotherapy or neoadjuvant treatment. - Incomplete or unsuitable imaging data for omics analysis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Develop an artificial intelligence model based on radiomics to predict the pathological complete response (pCR) rate following neoadjuvant therapy.; | — |
Secondary
| Measure | Time frame |
|---|---|
| The Predictive Value of Radiomic Features in Assessing Tumor Downstaging;The Association Between Radiomic Features and Long-Term Survival Outcomes (Overall Survival and Progression-Free Survival) in Patients;The Predictive Value of Imaging Features in Assessing Treatment-Related Adverse Reactions; | — |
Countries
China
Contacts
Public ContactYunjiu Gou
Gansu Provincial People's Hospital
Outcome results
None listed